EFFECT OF NEOADJUVANT CHEMOTHERAPY ON HORMONE RECEPTOR (ER, PR) STATUS AND HER-2/NEU EXPRESSION IN INDIAN BREAST CANCER PATIENTS: A PROSPECTIVE STUDY.

  • Department of General Surgery; Department of Trauma Surgery; Department of Endocrine Surgery, King George`s Medical University, UP, Lucknow, India.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • How to Cite This Article
  • Corresponding Author

Objective: This study was aimed to evaluate whether neoadjuvant chemotherapy (NACT) changes hormone receptor (ER, PR) status, Her-2/neu expression in carcinoma breast and role of outcome in planning adjuvant chemotherapy. Methods: 71 patients of locally advanced breast cancer (LABC), receiving NACT, were included. Core biopsy was done, to confirm invasive cancer, ER, PR and Her-2/neu expression before commencing NACT. Post treatment mastectomy specimen was analyzed for histopathology, ER, PR and Her-2/neu expression. Results: Immunohistochemistry (IHC) showed that ER positivity changed from 29.6% (n=21) to 28.2% (n=20) after treatment. While 70.4% (n=50) were ER- before treatment which increased to 71.8% (n=51) post chemotherapy (p=0.99). Pre-NACT, PR was positive in 31.0% (n=22) which changed to 28.2% (n=20) after treatment. 69% (n=49) were PR before treatment which increased to 71.8% (n=51) post chemotherapy (p=0.99). Her-2/neu was positive in 71.8% (n=51) before treatment which became 70.4% (n=50) post-treatment (P= 0.88). 26.8% were ER+ PR+ (n=19), 66.2% were ER-PR- (n=47), 4.2% were ER-PR+ (n=2) before NACT. Change in expression of hormone receptor status was noticed, ER+PR+ decreased to 25.4% (n=18), ER-PR- increased to 69.0% (n=49), ER-PR + decreased to 2.8% (n=2), no change was noticed in ER+PR- status. Tumor size was significantly reduced from pretreatment (39.37? 10.63 cms) to post-treatment (23.87?7.51 cms) (p < 0.05). Conclusion: On the basis of this study it was concluded that ER, PR and Her-2/neu status changes on IHC staining after NACT. So, IHC analysis on a post treatment tissue block should be repeated before planning adjuvant chemotherapy in patients of carcinoma breast.

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov;68(6):394-424.
  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
  3. Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia‐Pacific Journal of Clinical Oncology. 2017 Aug;13(4):289-95.
  4. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Archiv. 2005 May 1;446(5):489-96.
  5. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlb M. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocrine-related cancer. 2003 Mar 1;10(1):91-8.
  6. Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, Sugimura H. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre-and post-neoadjuvant chemotherapy. The Breast. 2008 Oct 1;17(5):523-7
  7. Piper GL, Patel NA, Patel JA, Malay MB, Julian TB. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. The American surgeon. 2004 Dec 1;70(12):1103.
  8. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirillo F, Bolsi G, Bertoli G, Alquati P, Dogliotti L. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer research. 1996;16(5B):3105-10.
  9. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. British journal of cancer. 2005 Jan;92(1):147.
  10. Colleoni M, Montagna E. Neoadjuvant therapy for ER-positive breast cancers. Annals of Oncology. 2012 Sep 1;23(suppl_10):x243-8.
  11. Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Phaneendra BV, Reddy MK. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology. 2015 Apr;36(2):117.
  12. Yang L, Zhong X, Pu T, Qiu Y, Ye F, Bu H. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. World journal of surgical oncology. 2018 Dec;16(1):51.
  13. Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. British journal of cancer. 2009 Nov;101(9):1529.
  14. Pedrini JL, Savaris RF, Schorr MC, Cambruzi E, Grudzinski M, Zettler CG. The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer. Tumori Journal. 2011 Nov;97(6):704-10.
  15. Ramteke P, Seenu V, Prashad R, Gupta SD, Iyer V, Deo SV, Gogia A, Mathur S. Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: Experience at a tertiary care centre in India. Indian journal of cancer. 2016 Jul 1;53(3):366.
  16. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. Journal of Clinical Oncology. 2006 Apr 20;24(12):1940-9.
  17. Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor?positive breast cancer. Journal of oncology practice. 2010 Aug 6;6(5):243-6.
  18. Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Achard JL, Gimbergues P, Cure H, Chollet P. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. The oncologist. 2007 Jun 1;12(6):636-43.
  19. Van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer treatment reviews. 2011 Oct 1;37(6):422-30.
  20. Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. The breast journal. 2008 Mar;14(2):141-6.
  21. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th?rlimann B, Senn HJ, Panel members, Albain KS, Andr? F, Bergh J. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology. 2013 Aug 4;24(9):2206-23.
  22. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th?rlimann B, Senn HJ, Panel Members. Strategies for subtypes?dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology. 2011 Jun 27;22(8):1736-47.

Saumya Singh, Vaibhav Jaiswal, Anand Kumar Mishra and Sandeep Tewari. (2019); EFFECT OF NEOADJUVANT CHEMOTHERAPY ON HORMONE RECEPTOR (ER, PR) STATUS AND HER-2/NEU EXPRESSION IN INDIAN BREAST CANCER PATIENTS: A PROSPECTIVE STUDY., Int. J. of Adv. Res., 7 (08), 1134-1144, ISSN 2320-5407. DOI URL: https://dx.doi.org/10.21474/IJAR01/9604

Vaibhav Jaiswal
Assistant Professor , Trauma Surgery , King George's Medical University, Lucknow , India

DOI:

Article DOI: 10.21474/IJAR01/9604      
DOI URL: https://dx.doi.org/10.21474/IJAR01/9604

Download Full Paper

Download PDF No. of Downloads: 29 | No. of Views: 100